Is ORAMED PHARMACEUTICALS INC. (ORMP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.3% / 30% | 108.4% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.3% / 33% | 108.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.2% / 33% | 91.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.3% / 33% | 108.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.2% / 33% | 91.4% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.6% | |
| Operating Margin | -650.5% | |
| Net Margin | 2192.6% | |
| Return on Equity (ROE) | 24.5% | |
| Return on Assets (ROA) | -4.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$8M |
| Free Cash Flow | -$8M |
| Total Debt | $372,000 |
| Debt-to-Equity | 0.4 |
| Current Ratio | 22.2 |
| Total Assets | $155M |
Price & Trading
| Last Close | $3.30 |
| 50-Day MA | $3.41 |
| 200-Day MA | $2.67 |
| Avg Volume | 215K |
| Beta | 1.3 |
|
52-Week Range
$1.82
| |
About ORAMED PHARMACEUTICALS INC. (ORMP)
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ORAMED PHARMACEUTICALS INC. (ORMP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ORAMED PHARMACEUTICALS INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ORAMED PHARMACEUTICALS INC.'s debt ratio?
ORAMED PHARMACEUTICALS INC.'s debt ratio is 0.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.2%.
What are ORAMED PHARMACEUTICALS INC.'s key financial metrics?
ORAMED PHARMACEUTICALS INC. has a market capitalization of $132M, trailing P/E ratio of 2.2. The company maintains a gross margin of 0.6% and a net margin of 2192.6%. Return on equity stands at 24.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.